The American Journal of Medicine
Volume 122, Issue 6, Supplement , Pages S25-S36 , June 2009

Incretin Therapies: Effects Beyond Glycemic Control

  • Sunder Mudaliar, MD

      Affiliations

    • Section of Diabetes/Metabolism, VA San Diego HealthCare System, San Diego California, USA
    • Department of Medicine, University of California at San Diego, San Diego, California, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Sunder Mudaliar, MD, VA San Diego HealthCare System (Mail Code: 111G), 3350 La Jolla Village Drive, San Diego, California 92161
    • ,
  • Robert R. Henry, MD

      Affiliations

    • Section of Diabetes/Metabolism, VA San Diego HealthCare System, San Diego California, USA
    • Department of Medicine, University of California at San Diego, San Diego, California, USA

  • Image Result

    Glycemic and extraglycemic effects of incretins/glucagonlike peptide–1 (GLP-1) agents. BP = blood pressure; CNS = central nervous system; GI = gastrointestinal.

    *Mediated centrally.

    Glycemic and extraglycemic effects of incretins/glucagonlike peptide–1 (GLP-1) agents. BP = blood pressure; CNS = central nervous system; GI = gastrointestinal.

    *Mediated centrally.

 Supported by the Department of Veteran Affairs. Dr. Mudaliar and Dr. Henry are employees of the Department of Veteran Affairs.

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(09)00278-2

doi: 10.1016/j.amjmed.2009.03.014

The American Journal of Medicine
Volume 122, Issue 6, Supplement , Pages S25-S36 , June 2009

Article Tools

* Image Usage & Resolution